

Curriculum Vitae



Massimiliano Bonifacio

General Informations

Birth date: 05/May/1978
Residence address: via Naronchi 42, 37030 Colognola ai Colli (VR), Italy
Work address: Dpt. of Medicine, Sect. of Hematology, University of Verona – Policlinico G.B. Rossi, Azienda Ospedaliera Universitaria Integrata di Verona P.le L.A. Scuro, 10, 37134 Verona, Italy
Mail address: massimiliano_bonifacio@yahoo.it; massimiliano.bonifacio@univr.it

Biography

Academic role Assistant Professor at the Dpt. of Medicine, Section of Hematology of the University of Verona from December 2013.

Education and training Post doc in Hematology at the University of Verona from 2008 to 2013
Academic stage at Instituto de Mastocitosis de Castilla - La Mancha (ES), in April 2011
Postgraduated in Hematology at the University of Verona in December 2007 (cum laude).
Certified Medical License in January 2004 (Ordine Medici Chirurghi della Provincia di Verona VR7353)
Graduated as MD at the University of Verona in October 2003 (cum laude).

Clinical experience from June 2008 clinical work at the Hematology Ambulatory – UOC Ematologia – Azienda Ospedaliera Universitaria Integrata di Verona, with particular interest in the management of Myeloproliferative Neoplasms:

- responsible clinician for the Chronic Myeloid Leukemia Outpatient Clinic
- co-responsible clinician for the Multidisciplinary Clinic for Mastocytosis (Ambulatorio Integrato per la Mastocitosi, GISM Verona)

Scientific interests

Fields of interest **Chronic Myeloid Leukemia**
Acute Lymphoblastic Leukemia
Ph-negative Myeloproliferative Neoplasms
Mastocytosis
Immunotherapy

Experience in ICH-GCP clinical trials - from December 2005 coinvestigator in protocols of the Italian cooperative group GIMEMA (Acute Leukemia and Chronic Myeloid Leukemia Working Parties).
- from 01 October 2014 Principal Investigator of the following national and international clinical trials: GIMEMA LAL1104, LAL1308, LAL1408, LAL1811, LAL1913, CML0713, CML0811, CML0912, CML1012, CML1113, CML1315, MT103-203, MT103-211, AMG20120216, AMG00103311, CINC424A2401, CAMN107AIC05.
- Coordinator of the Triveneto Group for Chronic Myeloid Leukemia and Principal Investigator of the CML Triveneto Registry.

Other Member of Società Italiana di Ematologia (SIE) from 2007 and Società Italiana di Ematologia Sperimentale (SIES) from 2015.

Disclosure of funding

I declare research funding from Novartis; consultancy fees from Ariad, Bristol Myers Squibb, Pfizer and Amgen.

List of publications

- Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, Diedrich H, Topp MS, Brüggemann M, Horst HA, Havelange V, Stieglmaier J, Wessels H, Haddad V, Benjamin JE, Zugmaier G, Nagorsen D, and Bargou RC. Blinatumomab for minimal residual disease in adults with B-precursor acute lymphoblastic leukemia. *Blood* 2018 Jan 22 doi:10.1182/blood-2017.08-798322 [e-pub ahead of print]
- Bonadonna P, Zanotti R, Pagani M, Bonifacio M, Scaffidi L, Olivieri E, Franchini M, Reccardini F, Costantino MT, Roncallo C, Mauro M, Boni E, Rizzini FL, Bilò MB, Marcarelli AR, and Passalacqua G. Anaphylactic reactions after discontinuation of hymenoptera venom immunotherapy: a clonal mast cell disorder should be suspected. *J Allergy Clin Immunol Pract* 2017; doi:10.1016/j.jaip.2017.11.025 [e-pub ahead of print]
- Bonifacio M, Zanotti R, Guardalben E, Mimola E, Scognamiglio F, Perbellini O, De Matteis G, Escribano L, Bonadonna P, Grigolato D, Bissoli S, Parisi A, Zamò A, Ambrosetti A, and Rossini M. Multiple large osteolytic lesions in a patient with systemic mastocytosis: a challenging diagnosis. *Clin Case Rep* 2017;5(12):1988-1991.
- Palandri F, Palumbo GA, Bonifacio M, Tiribelli M, Benevolo G, Martino B, Abruzzese E, D'Adda M, Polverelli N, Bergamaschi M, Tieghi A, Cavazzini F, Ibatì C, Crugnola M, Bosi C, Latagliata R, Di Veroli A, Scaffidi L, de Marchi F, Cerqui E, Anaclerico B, De Matteis G, Spinsanti M, Sabattini E, Catani L, Aversa F, Di Raimondo F, Vitolo U, Lemoli RM, Fanin R, Merli F, Russo D, Cuneo A, Bacchi Reggiani ML, Cavo M, Vianelli N, and Breccia M. Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. *Oncotarget* 2017;8(45):79073-79086.
- Iurlo A, Galimberti S, Abruzzese E, Annunziata M, Bonifacio M, Latagliata R, Pregno P, Ferrero D, Sorà F, Orlandi EM, Fava C, Cattaneo D, Bucelli C, Binotto G, Pungolino E, Tiribelli M, Gozzini A, Gugliotta G, Castagnetti F, Stagno F, Rege-Cambrin G, Martino B, Luciano L, Breccia M, Sica S, Bocchia M, Pane F, Saglio G, Rosti G, Specchia G, Cortelezzi A, and Baccarani M. Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. *Ann Hematol* 2018;97(1):95-100.
- Tiribelli M, Binotto G, Bonifacio M. The significance of early warning in chronic myeloid leukemia. *Expert Rev Hematol* 2017 Jun 15 [e-pub ahead of print].
- Gugliotta G, Castagnetti F, Breccia M, Albano F, Iurlo A, Intermesoli T, Abruzzese E, Levato L, D'Adda M, Pregno P, Cavazzini F, Stagno F, Martino B, La Barba G, Sorà F, Tiribelli M, Bigazzi C, Binotto G, Bonifacio M, Caracciolo C, Soverini S, Foà R, Cavo M, Martinelli G, Pane F, Saglio G, Baccarani M, and Rosti G. Incidence of secondary primary malignancies and related mortality in imatinib-treated chronic myeloid leukemia patients. *Haematologica* 2017 Jun 1 [e-pub ahead of print].
- Palandri F, Tiribelli M, Benevolo G, Tieghi A, Cavazzini F, Breccia M, Bergamaschi M, Sgherza N, Polverelli N, Crugnola M, Isidori A, Binotto G, Heidel FH, Buccisano F, Martino B, Latagliata R, Spinsanti M, Kallenberg L, Palumbo GA, Abruzzese E, Scaffidi L, Cuneo A, Cavo M, Vianelli N, and Bonifacio M. Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: results from an independent study. *Hematol Oncol* 2017 May 17 [e-pub ahead of print].
- Castagnetti F, Gugliotta G, Breccia M, Iurlo A, Levato L, Albano F, Vigneri P, Abruzzese E, Rossi G, Rupoli S, Cavazzini F, Martino B, Orlandi E, Pregno P, Annunziata M, Usala E, Tiribelli M, Sica S, Bonifacio M, Fava C, Gherlinzoni F, Bocchia M, Soverini S, Bochicchio MT, Cavo M, Giovanni M, Saglio G, Pane F, Baccarani M, and Rosti G. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib. *Am J Hematol* 2017 May 2 [e-pub ahead of print].
- Perricone M, Palandri F, Ottaviani E, Angelini M, Bagli L, Bellesia E, Donati M, Gemmati D, Zucchini P, Mancini S, Marchica V, Trubini S, De Matteis G, Di Zaccaro S, Favarato M, Fiorini A, Bolzonella C, Maccari G, Navaglia F, Gatti D, Toffolatti L, Orlandi L, Laloux V, Manfrini M, Galieni P, Giannini B, Tieghi A, Barulli S, Serino ML, Maccaferri M, Scortechini AR, Giuliani N, Vallisa D, Bonifacio M, Accorsi P, Salbe C, Fazio V, Gusella M, Toffoletti E, Salvucci M, Svaldi M, Gherlinzoni F, Cassavia F, Orsini F, and Martinelli G. Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: a study involving a consortium of 19 Italian laboratories. *Oncotarget* 2017;8(20):32608-32617.
- Bonadonna P, Bonifacio M, Zanotti R. Mast Cell Disorders in Drug Hypersensitivity. *Curr Pharm Des* 2016 Sep 28. [e-pub ahead of print]. [Review]
- Artuso A, Caimmi C, Tripi G, Viapiana O, Bonifacio M, Idolazzi L, Gavioli I, Gatti D, Zanotti R, and Rossini M. Longitudinal evaluation of bone mineral density and bone metabolism markers in patients with indolent systemic mastocytosis without osteoporosis. *Calcif Tissue Int* 2017;100(1):40-46.
- Latagliata R, Stagno F, Annunziata M, Abruzzese E, Iurlo A, Guarini A, Fava C, Gozzini A, Bonifacio M, Sorà F, Leonetti Crescenzi S, Bocchia M, Crugnola M, Castagnetti F, Capodanno I, Galimberti S, Feo C, Porri R, Pregno P, Rizzo M, Antolino A, Mauro E, Sgherza N, Luciano L, Tiribelli M, Russo Rossi A, Trawinska M, Vigneri P, Breccia M, Rosti G, and Alimena G. Frontline dasatinib treatment in a "real-life" cohort of patients older than 65 years with chronic myeloid leukemia. *Neoplasia* 2016;18(9):536-540.

List of publications (cont.)

- Iurlo A, Nobili A, Latagliata R, Bucelli C, Castagnetti F, Breccia M, Abruzzese E, Cattaneo D, Fava C, Ferrero D, Gozzini A, Bonifacio M, Tiribelli M, Pregno P, Stagno F, Vigneri P, Annunziata M, Cavazzini F, Binotto G, Mansueto G, Russo S, Falzetti F, Montefusco E, Gugliotta G, Storti S, D'Addosio AM, Scaffidi L, Cortesi L, Cedrone M, Rossi AR, Avanzini P, Mauro E, Spadea A, Celesti F, Giglio G, Isidori A, Crugnola M, Calistri E, Sorà F, Rege-Cambrin G, Sica S, Luciano L, Galimberti S, Orlandi EM, Bocchia M, Tettamanti M, Alimena G, Saglio G, Rosti G, Mannucci PM, and Cortelezzi A. Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. *Oncotarget* 2016;7(48):80083-80090.
- Pieri L, Bonadonna P, Elena C, Papayannidis C, Grifoni FI, Rondoni M, Girlanda S, Mauro M, Magliacane D, Elli EM, Iorno ML, Almerigogna F, Scarfi F, Salerno R, Fanelli T, Gesullo F, Fattori GC, Bonifacio M, Perbellini O, Artuso A, Soverini S, De Benedittis C, Muratori S, Pravettoni V, Cova V, Cortellini G, Ciceri F, Cortelezzi A, Martinelli G, Triggiani M, Merante S, Vannucchi AM, and Zanotti R. Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients. *Am J Hematol* 2016;91(7):692-699.
- Maino E, Bonifacio M, Scattolin AM, Bassan R. Immunotherapy approaches to treat adult acute lymphoblastic leukemia. *Expert Rev Hematol* 2016;9(6):563-577. [Review]
- Takam Kamga P, Bassi G, Cassaro A, Midolo M, Di Trapani M, Gatti A, Carusone R, Resci F, Perbellini O, Gottardi M, Bonifacio M, Nwabo Kamdje AH, Ambrosetti A, and Krampera M. Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia. *Oncotarget* 2016;7(16):21713-21727.
- Bonadonna P, Bonifacio M, Lombardo C, and Zanotti R. Hymenoptera allergy and mast cell activation syndrome. *Curr Allergy Asthma Rep* 2016;16(1):5. [Review]
- Bonadonna P, Bonifacio M, Lombardo C, and Zanotti R. Hymenoptera anaphylaxis and C-kit mutations: an unexpected association. *Curr Allergy Asthma Rep* 2015;15(8):49. [Review]
- Breccia M, Efficace F, Sica S, Abruzzese E, Cedrone M, Turri D, Gobbi M, Carella AM, Gozzini A, Usala E, Cavazzini F, Danise P, Tiribelli M, Binotto G, Pregno P, Bocchia M, Gaidano G, Crugnola M, Bonifacio M, Avanzini P, Celesti F, Guella A, Martino B, Annunziata M, Luciano L, Stagno F, Vallisa D, Pungolino E, Iurlo A, Rambaldi A, Nardiello I, Orlandi E, Gambacorti-Passerini C, and Alimena G. Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. *Leuk Res* 2015;39(10):1055-1059.
- Bonifacio M, Binotto G, Maino E, Calistri E, Marin L, Scaffidi L, Frison L, De Marchi F, Krampera M, Semenzato G, Fanin R, Ambrosetti A, and Tiribelli M. Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced possibility of subsequent optimal response. *Haematologica* 2015;100(8):e299-301.
- Tiribelli M, Binotto G, Calistri E, Maino E, Scaffidi L, Medeot M, Nabergoj M, Ambrosetti A, Semenzato G, Fanin R, and Bonifacio M. Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favourable response to frontline imatinib therapy. *Am J Hematol* 2015;90(7):e135-137.
- Rossini M, Viapiana O, Zanotti R, Tripi G, Perbellini O, Idolazzi L, Bonifacio M, Adami S, and Gatti D. Dickkopf-1 and Sclerostin serum levels in patients with Systemic Mastocytosis. *Calcif Tissue Int* 2015;96(5):410-416.
- Arribas AJ, Rinaldi A, Mensah AA, Kwee I, Cascione L, Robles EF, Martinez-Climent JA, Oscier D, Arcaini L, Baldini L, Marasca R, Thieblemont C, Briere J, Forconi F, Zamò A, Bonifacio M, Mollejo M, Facchetti F, Dirnhofer S, Ponzone M, Bhagat G, Piris MA, Gaidano G, Zucca E, Rossi D, and Berton F. DNA methylation-profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. *Blood* 2015;125(12):1922-1931.
- De Matteis G, Zanotti R, Colarossi S, De Benedittis C, Garcia-Montero A, Bonifacio M, Sartori M, Aprili F, Caruso B, Paviati E, Carli G, Perbellini O, Zamò A, Bonadonna P, Pizzolo G, Guidi G, Martinelli G, and Soverini S. The impact of sensitive KIT D816V detection on recognition of indolent systemic mastocytosis. *Leuk Res* 2015;39(3):273-278.
- Soverini S, De Benedittis C, Papayannidis C, Paolini S, Venturi C, Iacobucci I, Luppi M, Bresciani P, Salvucci M, Russo D, Sica S, Orlandi E, Intermesoli T, Gozzini A, Bonifacio M, Rigolin GM, Pane F, Baccarani M, Cavo M, and Martinelli G. Drug resistance and BCR-ABL kinase domain mutations in philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: the main changes are in the type of mutations, but not in the frequency of mutation involvement. *Cancer* 2014;120(7):1002-1009.
- Zanotti R, Lombardo C, Passalacqua G, Caimmi C, Bonifacio M, De Matteis G, Perbellini O, Rossini M, Schena D, Busa M, Marcotulli MC, Bilò MB, Franchini M, Marchi G, Simioni L, and Bonadonna P. Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels. *J Allergy Clin Immunol* 2015;136(1):135-139.
- Castagnetti F, Gugliotta G, Baccarani M, Breccia M, Specchia G, Levato L, Abruzzese E, Rossi G, Iurlo A, Martino B, Pregno P, Stagno F, Cuneo A, Bonifacio M, Gobbi M, Russo D, Gozzini A, Tiribelli M, de Vivo A, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G; on behalf of the GIMEMA CML Working Party. Differences among young adults, adults, and elderly chronic myeloid leukemia patients. *Ann Oncol* 2015;26(1):185-192.

List of publications (cont.)

- Bonifacio M, Binotto G, Calistri E, Maino E, and Tiribelli M for the Gruppo Triveneto LMC. EUTOS score predicts early optimal response to imatinib according to the revised 2013 ELN recommendations. *Ann Hematol* 2014;93(1):163-164.
- Tiribelli M, Bonifacio M, Calistri E, Binotto G, Maino E, Marin L, Guardalben E, Branca A, Gherlinzoni F, Semenzato G, Sancetta R, Pizzolo G, and Fanin R. EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukemia. *Leuk Res* 2013;37(11):1457-1460.
- Chiaretti S, Brugnoletti F, Tavolaro S, Bonina S, Paoloni F, Marinelli M, Patten N, Bonifacio M, Kropp MG, Sica S, Guarini A, and Foà R. TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy. *Haematologica* 2013;98:e59-61
- Zanotti R, Simioni L, Garcia-Montero AC, Perbellini O, Bonadonna P, Caruso B, Jara-Acevedo M, Bonifacio M, and De Matteis G. Somatic D816V mutation in a case of adult-onset familial mastocytosis. *J Allergy Clin Immunol* 2013;131(2):605-607.
- Munari E, Rinaldi M, Ambrosetti A, Bonifacio M, Bonalumi A, Chilosi M, and Zamò A. Absence of TCL1A expression is a useful diagnostic feature in splenic marginal zone lymphoma. *Virchows Arch* 2012;461(6):677-685.
- Bonifacio M, Rigo A, Guardalben E, Bergamini C, Cavalieri E, Fato R, Pizzolo G, Suzuki H, and Vinante F. α -bisabolol is an effective proapoptotic agent against BCR-ABL(+) cells in synergism with Imatinib and Nilotinib. *PLoS One* 2012;7(10):e46674.
- Rigo A, Gottardi M, Damiani E, Bonifacio M, Ferrarini I, Mauri P, and Vinante F. CXCL12 and [N33A]CXCL12 in 5637 and HeLa cells: regulating HER1 phosphorylation via calmodulin/calcineurin. *PLoS One* 2012;7(4):e34432.
- Todeschini G, Bonifacio M, Tecchio C, Balter R, Carli G, Stefani PM, Adami F, Zamò A, Dei Tos AP, Marino F, Gherlinzoni F, Marradi P, Semenzato G, and Pizzolo G. Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia. *Am J Hematol* 2012;87(1):22-25.
- Rossini M, Zanotti R, Bonadonna P, Artuso A, Caruso B, Schena D, Vecchiato D, Bonifacio M, Viapiana O, Gatti D, Senna G, Riccio A, Passalacqua G, Pizzolo G, and Adami S. Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. *Bone* 2011;49(4):880-885.
- Cavalieri E, Rigo A, Bonifacio M, Carcereri de Prati A, Guardalben E, Bergamini C, Fato R, Pizzolo G, Suzuki H, and Vinante F. Pro-apoptotic activity of α -bisabolol in preclinical models of primary human acute leukemia cells. *J Transl Med* 2011;9:45.
- Zanotti R, Bonadonna P, Bonifacio M, Artuso A, Schena D, Rossini M, Perbellini O, Colarossi S, Chilosi M, and Pizzolo G. Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis. *Haematologica* 2011;96(3):482-484.
- Todeschini G, Bonifacio M, Tecchio C, Dalceggio D, Benedetti F, Gabbas A, and Pizzolo G. A preliminary experience with the HyperCHiDAM Verona intensive chemotherapy regimen in heavily pretreated refractory Hodgkin's lymphoma. *Hematol Oncol* 2011;29(3):151-153.
- Rigo A, Gottardi M, Zamò A, Mauri P, Bonifacio M, Krampera M, Damiani E, Pizzolo G, and Vinante F. Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12. *Mol Cancer* 2010;9:273.
- Tecchio C, Colato C, Bonifacio M, Krampera M, Maluta S, Pizzolo G, and Girolomoni G. Plasmacytoid dendritic cell leukemia: a rapidly evolving disease presenting with skin lesions sensitive to radiotherapy plus hyperthermia. *Oncologist* 2009;14:1205-1208.
- Bonifacio M, Perbellini O, Pizzolo G. T-cell acute lymphoblastic leucemia and T-cell lymphoblastic lymphoma: therapy in adults. *Hematol Meeting Reports* 2009;3(1):115-122.
- Author of more than 50 and first author of 15 abstracts presented at national and international congresses.
- I authorize to use my personal data according to the Italian law (D.Leg. 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali").

01 / Mar / 2018

